BEAM:NSD-Beam Therapeutics Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 24.23

Change

0.00 (0.00)%

Market Cap

USD 2.20B

Volume

2.17M

Analyst Target

USD 32.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-16 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 123.21B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 76.39B
ARGX argenx NV ADR

N/A

USD 37.97B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 31.94B
ONC BeiGene, Ltd.

N/A

USD 28.70B
RPRX Royalty Pharma Plc

N/A

USD 18.65B
SMMT Summit Therapeutics PLC

N/A

USD 17.01B
UTHR United Therapeutics Corporatio..

N/A

USD 14.37B
INCY Incyte Corporation

N/A

USD 14.22B
MRNA Moderna Inc

N/A

USD 13.74B

ETFs Containing BEAM

XDNA 13.90 % 0.00 %

N/A

N/A
TYNE 11.03 % 0.00 %

N/A

N/A
ARKG ARK Genomic Revolution ET.. 5.03 % 0.75 %

N/A

USD 1.06B
GNOG:LSE Global X Genomics & Biote.. 4.55 % 0.00 %

N/A

USD 9.42M
ARCG:LSE ARK Genomic Revolution UC.. 4.46 % 0.00 %

N/A

USD 9.51M
GNOM Global X Genomics & Biote.. 4.38 % 0.00 %

N/A

USD 0.06B
ARKG:LSE ARK Genomic Revolution UC.. 3.91 % 0.00 %

N/A

USD 9.33M
WELL:LSE Hanetf Icav - Han-Gins He.. 0.00 % 0.00 %

N/A

N/A
IBBJ 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -2.30% 68% D+ 56% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -2.30% 68% D+ 56% F
Trailing 12 Months  
Capital Gain -31.57% 57% F 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -31.57% 57% F 29% F
Trailing 5 Years  
Capital Gain 61.43% 80% B- 61% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 61.43% 80% B- 56% F
Average Annual (5 Year Horizon)  
Capital Gain 27.42% 70% C- 80% B-
Dividend Return 27.42% 70% C- 79% B-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 125.96% 32% F 17% F
Risk Adjusted Return 21.77% 80% B- 54% F
Market Capitalization 2.20B 89% A- 80% B-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector